Skip to main content
Atrás
Watch Compare

Quince Therapeutics, Inc.

Calidad de datos: 83%
QNCX
Nasdaq Manufacturing Chemicals
$0.14
▲ $0.01 (10.19%)
Cap. Mercado: 6.89 M
Precio
$0.12
Cap. Mercado
6.89 M
Rango del Día
—
Rango de 52 Semanas
—
Volumen
—
Apertura —
Promedio 50D / 200D
—
Promedio 50D / 200D
—

Quick Summary

Puntos Clave

Debt/Equity of 0.00 — conservative balance sheet
Negative free cash flow of -38.98 M

Crecimiento

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-890.64%
Below sector avg (-53.34%)
ROIC-41.40%
Net MarginN/A
Op. MarginN/A

Seguridad

Debt / Equity
0.00
Below sector avg (0.31)
Current Ratio1.12
Interest CoverageN/A

Valoración

PE (TTM)
-0.12
Above sector avg (-1.47)
P/B Ratio6.50
EV/EBITDAN/A
Dividend YieldN/A

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Manufacturing (1364 pares)
Métrica Acción Mediana del Sector
P/E -0.1 -1.5
P/B 6.5 1.6
ROE % -890.6 -53.3
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E 0.0 0.3

Precio Objetivo de Analistas

1 analista
Hold
Actual
$0.14
-100.0%
Objetivo
$0.00
$0.00
$0.00
$0.00
Pronóstico
P/E Futuro -0.12
EPS Futuro -$1.17
Ingresos Est. 0.0

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2026 -$1.17
-$1.53 – -$0.81
 0.0 2

Sorpresas de Ganancias

Últimos 4 trimestres
Trimestre EPS Est. EPS Real Sorpresa
Q32025 -$0.22 -$0.25 -12.4%
Q22025 -$0.23 -$0.33 -39.8%
Q12025 -$0.23 -$0.34 -47.8%
Q42024 -$0.10 -$0.28 -180.0%

ETFs Holding This Stock

BRSIX BRSIX
0.10% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -56.98 M
ROE -890.64% ROA -50.18%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -38.98 M
ROIC -41.40% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.00 Current Ratio 1.12
Interest Coverage N/A Asset Turnover N/A
Working Capital 3.16 M Tangible Book Value -66.67 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.12 Forward P/E N/A
P/B Ratio 6.50 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -565.88%
Market Cap 6.89 M Enterprise Value 435,800.0
Per Share
EPS (Diluted TTM) -1.20 Revenue / Share N/A
FCF / Share -0.70 OCF / Share -0.69
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 68.41%
SBC-Adj. FCF -44.02 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue — — — — —
Net Income -56.83 M -31.39 M -51.66 M -89.95 M -76.85 M
EPS (Diluted) -1.31 -0.84 -1.54 — —
Gross Profit — — — — —
Operating Income -57.29 M -34.62 M -52.02 M -90.32 M -78.89 M
EBITDA — — — — —
R&D Expenses 18.59 M 9.45 M 25.18 M 60.80 M 61.31 M
SG&A Expenses — — — — —
D&A 186,000.0 322,000.0 204,000.0 344,000.0 332,000.0
Interest Expense — — — — 957,000.0
Income Tax 87,000.0 197,000.0 -284,000.0 — 0.0

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 114.48 M 167.90 M 103.91 M 133.23 M 189.47 M
Total Liabilities 84.33 M 82.82 M 3.32 M 14.64 M 17.20 M
Shareholders' Equity 30.15 M 85.08 M 100.59 M 118.59 M 172.26 M
Total Debt 14.32 M 13.43 M — — —
Cash & Equivalents 40.80 M 75.10 M 90.20 M 106.80 M 133.80 M
Current Assets 44.04 M 77.44 M 93.75 M 111.67 M 137.86 M
Current Liabilities 7.28 M 9.57 M 3.07 M 14.22 M 17.00 M